Analyst Gil Blum of Needham maintained a Buy rating on Autolus Therapeutics, retaining the price target of $10.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Gil Blum’s rating is based on several positive developments at Autolus Therapeutics. The company has shown promising progress with its product Aucatzyl, which is being used to treat a significant portion of relapsed/refractory adult acute lymphoblastic leukemia (r/r ALL) patients. Despite a temporary sales plateau expected in the third quarter of 2025 due to changes in CMS reimbursement, sales are anticipated to pick up again in the fourth quarter. Aucatzyl’s lower toxicity rates and longer response duration compared to competitors are key differentiators that enhance its market appeal.
Moreover, Autolus is focusing on expanding its market reach by increasing penetration in key ALL centers and moving Aucatzyl into earlier treatment lines. The company is also planning to launch Aucatzyl in select European countries with confidential pricing agreements and is working on expanding its label through studies in pediatric ALL. Additionally, Autolus is making strides in improving its manufacturing processes, which could lead to higher gross margins in the future. These strategic initiatives and operational efficiencies form the basis of Gil Blum’s Buy rating for Autolus Therapeutics.
According to TipRanks, Blum is a 4-star analyst with an average return of 4.7% and a 40.24% success rate. Blum covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Sarepta Therapeutics, and Celcuity.